亨利希恩 HSIC

Mr. Stanley M. Bergman has been with the Company since 1980, Organizations: Chair, Dean's Strategic Advisory Council, New York University College of Dentistry (1998-present); Chairman of the Board, The University of the Witwatersrand Fund, Inc. (2004-present); Governor and Former Co-Chair, Global Health & Healthcare Governors Community, World Economic Forum (Governor 2004-present; Co-Chair 2018-2020); Director Emeritus, Board of Overseers, The University of Pennsylvania School of Dental Medicine (Director 1997-2019; Director Emeritus 2019-present); Honorary member, Alpha Omega International Dental Society; Honorary member, American Dental Association (ADA). Education: Certified Public Accountant (CPA); South African Chartered Accountant (CA SA); Graduate, University of the Witwatersrand in South Africa. Awards & Recognition: Awarded Honorary Doctorates: The University of the Witwatersrand, Western University of Health Sciences, Hofstra University, A.T. Still University's Arizona School of Dentistry and Oral Health, Case Western Reserve University, Farmingdale State College (SUNY), The Hebrew University of Jerusalem. Awarded Honorary Fellowships: King's College London - Dental Institute, International College of Dentists; Recognized as 2017 CEO of the Year by Chief Executive Magazine, Recipient, Ellis Island Medal of Honor, Recipient, CR Magazine Corporate Responsibility Lifetime Achievement Award. Mr. Bergman resigning as Chief Executive Officer effective March 2, 2026 and will continue as Chairman of the Board. Mr. Stanley M. Bergman retired from Chairman of the Board and was named Chairman Emeritus effective May 21, 2026.

Mark E. Mlotek has been our Executive Vice President and Chief Strategic Officer since 2012. Mr. Mlotek was adirector from 1995 to May 2025. Prior to his current role, Mr. Mlotek was Senior Vice President and subsequentlyExecutive Vice President of the Corporate Business Development Group between 2000 and 2012. Prior to that, Mr.Mlotek was Vice President, General Counsel and Secretary from 1994 to 1999 and became a director in1995. Prior to joining us, Mr. Mlotek was a partner in the law firm of Proskauer Rose LLP, counsel to us,specializing in mergers and acquisitions, corporate reorganizations and tax law from 1989 to 1994.On July 30, 2026, Henry Schein, Inc. announced that, effective October 30, 2026, Mark E. Mlotek, the Company's Executive Vice President and Chief Strategic Officer will transition out of their current roles into senior advisory roles.

Michael S. Ettinger has been our Executive Vice President and Chief Operating Officer since 2022. Prior to hiscurrent position, Mr. Ettinger served as Senior Vice President, Corporate & Legal Affairs, Chief of Staff andSecretary from 2015 to 2022, Senior Vice President, Corporate & Legal Affairs and Secretary from 2013 to 2015,Corporate Senior Vice President, General Counsel & Secretary from 2006 to 2013, Vice President, GeneralCounsel and Secretary from 2000 to 2006, Vice President and Associate General Counsel from 1998 to 2000 andAssociate General Counsel from 1994 to 1998. Before joining us, Mr. Ettinger served as a senior associate withBower & Gardner and as a member of the Tax Department at Arthur Andersen.On July 30, 2026, Henry Schein, Inc. announced that, effective October 30, 2026, Michael S. Ettinger, the Company's Executive Vice President and Chief Operating Officer will transition out of their current roles into senior advisory roles.

Andrea Albertinihas been Chief Executive Officer, Global Distribution Group and Technology Group since January 2025. In this role, Mr. Albertini is responsible for our Global Distribution and Value-Added Servicessegment and our Global Technology segment. Mr. Albertini joined us in 2013 and has held several positions withinthe organization including Chief Executive Officer, International Distribution Group, President, InternationalDistribution Group, President of our EMEA Dental Distribution Group, and Vice-President of International DentalEquipment. Prior to joining Henry Schein, Mr. Albertini held leadership positions at Cefla Dental Group andCastellini.

Ronald N. South has been our Senior Vice President and Chief Financial Officer (and principal financial officerand principal accounting officer) since 2022. Prior to holding his current position, Mr. South was our VicePresident Corporate Finance since 2008, and Chief Accounting Officer from 2013 until 2022. Prior to joining us in2008 as our Vice President, Corporate Finance, Mr. South held leadership roles at Bristol-Myers Squibb andPepsiCo, and held several roles of increasing responsibility with PricewaterhouseCoopers LLP, where he advisedclients located in the United States, Europe, and Latin America. Mr. South is a Certified Public Accountant.

Mr. Philip A. Laskawy has been a director since 2002 and has served as our Lead Director since 2012. Other Boards:Covetrus, Inc. (2019-2022) (Independent Chairman and Nominating and Governance Committee member); General Motors Corporation (2009-2013) (Finance Committee member); Fannie Mae (2008-2014) (Chairman); Lazard Ltd. (2008-2023) (Audit Committee Chair and Compensation Committee member); Discover Financial Services (2007-2008); Loews Corporation (2003-2023) (Audit Committee member); Goodyear Tire & Rubber Co. (2001-2002); The Progressive Corporation (2001-2007); EY, LLP (1994-2001). Organizations: Former Board Member, American Institute of Certified Public Accountants; Former Chairman and Vice Chairman of the International Accounting Standards Committee Foundation; Former Member, 1999 Blue Ribbon Committee on Improving the Effectiveness of Corporate Audit Committees. Education:Certified Public Accountant (CPA); B.A., University of Pennsylvania Wharton School of Business (Economics). Professional Experience: Lead Director, Henry Schein, Inc. (2012-Present); Retired Chairman and CEO, EY LLP (1994-2001); Former Vice Chairman, Managing Partner (New York Region) and Member of the Management Committee, EY LLP (1985-1994); Former Managing Partner (New York Office), EY LLP (1981-2001).

Ms. Deborah M. Derby has been a director since 2021. Professional Experience: Operating Partner, Garnett Station Partners (October 2024-Present); Former President and CEO, Carrols Restaurant Group, Inc. (May 2023-June 2024); Former President, Horizon Group USA, Inc. (2016-2020); Former Executive Vice President and Vice Chairman, Toys R Us, Inc. (2013-2015); Former Chief Administrative Officer, Toys R Us, Inc. (2009-2012); Former President of Babies R Us, Toys R Us, Inc. (2006-2009) and served in various human resource positions of increasing responsibility (2000-2006); Former Employment Law Attorney, Whirlpool Corporation (1992-2000); Former Corporate Attorney at a large law firm in Michigan (1990-1992). Other Boards:Carrols Restaurant Group, Inc. (2018-May 2024) (Compensation Committee Chair); Vitamin Shoppe, Inc. (2012-2019) (Compensation Committee Chair, Nominating and Governance Committee member, and Strategic Committee member). Organizations: Former Board Member, Toys R Us Children's Foundation; Former Board Member, K.I.D.S. (Kids in Distressed Situations). Education: J.D., University of Notre Dame; M.B.A., University of Notre Dame; B.A., Harvard University (General Studies, Concentrating in Economics).

Mr. Kurt P. Kuehn has been a director since 2016. Mr. Kuehn was Chief Financial Officer of United Parcel Service, Inc. (UPS), a global leader in logistics, from 2008 until 2015. Prior to his appointment as CFO, Mr. Kuehn was Senior Vice President, Worldwide Sales and Marketing, leading the transformation of the sales organization to improve the global customer experience. Mr. Kuehn was UPS' first Vice President of Investor Relations, taking the company public in 1999 in one of the largest IPOs in U.S. history. Since he joined UPS as a driver in 1977, Mr. Kuehn's UPS career included leadership roles in sales and marketing, engineering, operations and strategic cost planning. He was also a member of UPS' corporate sustainability steering committee, sponsored UPS' first sustainability report and supported the sustainability activities of UPS for over 10 years. Mr. Kuehn brings to the Company's Board of Directors extensive experience with distribution logistics, and as the CFO of UPS for eight years, comprehensive knowledge in corporate finance and accounting. Additionally, the Board of Directors values Mr. Kuehn's insights in strategic cost planning and the needs of global customers, as well as his strategic sustainability and environmental, social and governance experience. Mr. Kuehn serves as the Board of Directors' advisor to the Company's Environmental Impact Council. Mr. Kuehn was awarded the 2015 E3 Lifetime Service Award for sustainability support by the Metro Atlanta Chamber and the 2013 C.K. Prahalad Award for Global Business Sustainability Leadership from the Corporate Eco Forum. Additionally, Mr. Kuehn has published several articles on sustainability in various journals including co-authoring an article on the financial case for sustainability titled Sustainability a CFO Can Love (published in the Harvard Business Review). Mr. Kuehn is a director of LocatorX, a private technology company. Mr. Kuehn is currently an active member of the Standards Board of the Sustainability Accounting Standards Board (SASB). During the past five years, Mr. Kuehn served as a director of NCR Corporation. Education:Completed the Wharton Advanced Management Program (University of Pennsylvania); M.B.A., University of Miami; Attended Yale University.

Mr. Mohamad Ali has been a director since 2021. Senior Vice President and Head of IBM Consulting, IBM Corporation (July 2024-Present); Former Senior Vice President and Chief Operating Officer of IBM Consulting, IBM Corporation (September 2023-June 2024); Former CEO and Director, IDG, Inc. (2019-May 2023); Former President and CEO, Carbonite, Inc. (2014-2019); Former Chief Strategy Officer, HP Inc. (2012-2014);Former President, Avaya Global Services, Avaya LLC (2009-2012);Former Vice President (Business Strategy, Information Management Division), IBM Corporation (1996-2009). Other Boards IDG, Inc. (2019-2023); iRobot Corporation (2015-June 2024); Carbonite, Inc. (2014-2019); City National Bank (2013-2015). Organizations: Board Member and Former Chairperson, Massachusetts Technology Leadership Council; Former Board Member, Oxfam America. Education: M.S., Stanford University (Electrical Engineering); B.S., Stanford University (Computer Engineering); B.A., Stanford University (History)

Ms. Anne H. Margulies has been a director since 2018. Ms. Margulies was the Vice President and Chief Information Officer for Harvard University from 2010 until her retirement in 2021. She was responsible for information technology strategy, policies and services for the university. Prior to that, she was the Assistant Secretary for Information Technology and Chief Information Officer for the Commonwealth of Massachusetts from 2007 to 2010, responsible for the strategy, policies and overall management of information technology across the state's government. With information technology playing an increasingly important role in the Company's business, the Board of Directors values Ms. Margulies' more than 35 years of strategic information technology leadership and information technology expertise, including in the areas of cybersecurity policy and risk management. Ms. Margulies serves as the Board of Directors' co-lead for the Company's Diversity and Inclusion Council. She currently serves as a member of the board of directors of SomaLogic, Inc. (and is Chair of its compensation committee and a member of its audit committee and nominating and corporate governance committee) and HarborOne Bancorp, Inc. (and is a member of its compensation committee). She is also a member of the advisory board of the Advanced Cyber Security Center, a New England-based regional organization committed to strengthening its members' cybersecurity defenses and preparing the region's response to large scale cyber threats. In 2022, Ms. Margulies completed the Digital Directors Network's Masterclass on Systemic Cyber Risk for Corporate Directors. Ms. Margulies was a member of the Massachusetts Technology Collaborative Board from 2012 to 2021. In 2015, Ms. Margulies was named 2015 Boston CIO Leader of the Year by the Boston Business Journal along with the Boston CIO Leadership Association, in 2017, she was named by IDG Enterprises to the 2017 CIO Hall of Fame in CIO Magazine, and in 2019, she was awarded an honorary Doctorate in engineering from the Universitat Politecnica de Valencia. Education: B.A., State University of New York at Plattsburgh.

On December 13, 2023, the Board appointed Carole T. Faig as a new independent director effective immediately. Prior to retiring in July 2021, from her 38-year career at Ernst & Young LLP (EY), Ms. Faig served in several leadership roles, including U.S. Health Leader and West Region Health and Life Sciences Leader, where she was responsible for developing and driving EY's strategy to grow its health care practice in a rapidly changing environment. Ms. Faig brings to Henry Schein extensive expertise in finance, audit, and public accounting and particular experience in the health care sector, including hospitals, health insurance, biotechnology, and medical device companies. Prior to retiring in July 2021, from her 38-year career at Ernst & Young LLP (EY), Ms. Faig served in several leadership roles, including U.S. Health Leader and West Region Health and Life Sciences Leader, where she was responsible for developing and driving EY's strategy to grow its health care practice in a rapidly changing environment. Ms. Faig holds a Bachelor of Business Administration in accounting from Sam Houston State University and is a certified public accountant. Ms. Faig is currently a member of the boards of directors of three companies, where she serves as the Audit Committee Chair: Cue Health, a Nasdaq-listed company, and Affinia Therapeutics and QuVa Pharma, private equity-backed private businesses. A champion for diversity, she served on EY's Gender Equity Task Force and was awarded EY's Chairman's Value Award and Americas Assurance Inclusive Leadership Award in recognition of her commitment to building an inclusive workplace.

Dr. Reed V. Tuckson, M.D. has been a director since 2021. Since 2014, Dr. Tuckson has served as Managing Director of Tuckson Health Connections, LLC, a private health and medical care consulting business. He is also the co-founder and Convener of the Black Coalition Against COVID-19 and the co-founder and Chairman of the Board of the Coalition For Trust In Health & Science. Prior to Tuckson Health Connections, Dr. Tuckson enjoyed a long tenure as Executive Vice President and Chief of Medical Affairs of United Health Group from 2006 until 2013. Dr. Tuckson previously served as Senior Vice President, Professional Standards of the American Medical Association, Commissioner of Public Health for the District of Columbia, Senior Vice President of the March of Dimes Birth Defects Foundation and President of the Charles R. Drew University of Medicine and Science. Additionally, he has been appointed to leadership roles at the National Academy of Medicine, and has been a member of numerous federal advisory committees and corporate, non-profit and academic boards, including his past service on the board of trustees of Howard University, where he served as Chair of the Health Sciences Committee. The Board of Directors values Dr. Tuckson's more than 35 years of experience as a healthcare professional, his recognition as a leader in his field and his engagement in nearly every sector of the health and medical care industries. Dr. Tuckson serves as the Board of Directors' co-lead for the Company's Diversity and Inclusion Council. Dr. Tuckson was recognized several times as one of the 50 Most Influential Physician Executives by Modern Healthcare Magazine, named as one of the 100 Most Powerful Executives in Corporate America by Black Enterprise Magazine in 2009, and as Washingtonian of the Year by Washingtonian Magazine in 1998. He is also the author of The Doctor in the Mirror, an ongoing book and online senior patient activation and education project. Dr. Tuckson currently serves on the board of directors of Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. During the past five years, Dr. Tuckson served as a director of CTI BioPharma Corp; Acasti Pharma, Inc. (2013-2016); LifePoint Health, Inc. (2014-2018); Baxter International, Inc. (1996-1998). Education: Completed the University of Pennsylvania Hospital's General Internal Medicine Residency and Fellowship programs, where he was also a Robert Wood Johnson Foundation Clinical Scholar studying at the Wharton School of Business.

The company announced that its Board of Directors has elected William K. Dan Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14 years as Executive Vice President at Danaher Corporation (NYSE: DHR), where he oversaw multiple business segments including Danaher's dental portfolio. Mr. Daniel also played a key role in advancing Danaher's business systems and culture, while also serving as a Board Director at Envista Holdings Corporation (NYSE: NVST) when it was spun off from Danaher.

Mr. Max C. Lin was appointed effective January 29, 2025. Max Lin leads the Health Care industry team within KKR. He is a member of the Investment Committee and Portfolio Management Committee for Americas Private Equity, the Health Care Strategic Growth Investment Committee, and the Global Conflicts and Compliance Committee. Since joining KKR in 2005, Mr. Lin has overseen a number of investments in the areas of dental services and other health care providers, medical products and equipment, and health care software and information technology. He holds a B.S. and B.A.S., summa cum laude, from the University of Pennsylvania and an M.B.A. from Harvard Business School.

Tom Popeck has been our Chief Executive Officer, Henry Schein Products Group since January 2025. In this role,Mr. Popeck is responsible for our Global Specialty Products segment. Since joining us in 2019, Mr. Popeck hasheld several key positions including Chief Executive Officer, Healthcare Specialties Group, and President of ourHealthcare Specialties Group. Prior to joining Henry Schein, Mr. Popeck held various sales leadership and generalmanagement executive positions at Stryker.

Kelly Murphy has been our Senior Vice President and General Counsel since 2021. In 2025, in addition to herglobal legal responsibilities, her role expanded to include leadership of our Regulatory and Compliance functions. Since joining us in 2011, Ms. Murphy has held several key positions of increasing responsibility within the legalfunction, most recently serving as Deputy General Counsel.

David Kochman has been our Senior Vice President, Chief Corporate Affairs Officer since January 2025. Mr.Kochman joined us in 2015 and has held roles of increasing responsibility, including Vice President, ChiefCorporate Affairs Officer, and Vice President, Corporate Affairs & Deputy Chief of Staff, Office of the CEO. Priorto joining Henry Schein, Mr. Kochman served as General Counsel and Corporate Development Officer for aprivately held company and was previously a Partner at the law firm Reed Smith LLP.

James Mullins has been our Senior Vice President of Global Supply Chain since 2018. Mr. Mullins joined us in1988 and has held a number of key positions with increasing responsibility, including Global Chief CustomerService Officer.

R. Steven Boggan has been our Chief Executive Officer, Global Oral Reconstruction Group since July 2025. AsCEO of our Global Oral Reconstruction Group, which is part of our Global Specialty Products segment, Mr.Boggan leads commercial operations in the Americas, global marketing, and R&D. Mr. Boggan joined HenrySchein, as the President and CEO of BioHorizons, which we acquired in 2014. Mr. Boggan joined BioHorizons in1995 and was promoted to President and CEO in 2000. Prior to BioHorizons, Mr. Boggan was employed at DowCorning Wright and Wright Medical Technology from 1989 until 1995.

Christine Sheehy has been our Senior Vice President, Chief Human Resources Officer since November 2024. Ms.Sheehy joined us in 2019 and has held several key positions with increasing responsibility, including Vice Presidentof the Human Resources Business Partner function for our North America Distribution Group, HealthcareSpecialties Group, several Global Oral Reconstruction businesses, and our Corporate Functions. Prior to joiningHenry Schein, Ms. Sheehy held various leadership positions at Standard Chartered Bank and Banco Real

Christopher Pendergast has been our Senior Vice President and Chief Technology Officer since 2018. Prior tojoining us, Mr. Pendergast was employed by VSP Global from 2008 to 2018, most recently as the ChiefTechnology Officer and Chief Information Officer. Prior to VSP Global, Mr. Pendergast served in roles ofincreasing responsibility at Natural Organics, Inc., from 2006 to 2008, IdeaSphere Inc./Twinlab Corporation from2000 to 2006, IBM Corporation from 1987 to 1994 and 1998 to 2000 and Rohm and Haas from 1994 to 1998

On January 10, 2026, the Board of Directors of Henry Schein, Inc. appointed Mr. Frederick Lowery as Chief Executive Officer and director of the Company, effective March 2, 2026. Mr. Lowery, 54, comes to the Company from Thermo Fisher Scientific Inc., where he has most recently served as Executive Vice President and President, Laboratory Products and BioProduction. Prior to this role, he served as Senior Vice President and President, Customer Channels since January 2021. He joined Thermo Fisher Scientific Inc. in 2005 as head of operations for the Molecular BioProducts business of Fisher Scientific International.